Contact OnePath and get connected with a Case Manager.
Shire believes that the costs associated with rare disease treatments should not be a barrier to patient access. The OnePath Co-pay Assistance Program will continue to assist eligible patients in the United States who have commercial insurance with their Shire co-pay expenses. This program will also cover certain infusion expenses for eligible patients, up to the program maximum, regardless of financial status.* Eligible Shire co-pay expenses and certain infusion charges will be covered at 100%, up to the program maximum.
* Additional program restrictions and eligibility requirements apply. Not valid for prescriptions eligible to be reimbursed by Medicaid, Medicare, or other state or federal programs. Coverage of certain infusion charges does not apply for patients residing in MA, MI, MN, RI, and VT. Offer good only in the United States. Offer void where prohibited by law, taxed, or restricted. Shire reserves the right to rescind, revoke, or amend this offer at any time without notice.
VPRIV® (velaglucerase alfa for injection) is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.